Research programme: dianexin based therapeutics - Lawson Health Research Institute/Yabao PharmaceuticalsAlternative Names: Annexin A5 based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals
Latest Information Update: 06 Aug 2015
At a glance
- Originator Lawson Health Research Institute; Yabao Pharmaceutical Group
- Class Biological peptides; Calcium binding proteins; Recombinant fusion proteins
- Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Sepsis